- Previous Close
0.4250 - Open
0.4000 - Bid 0.4500 x --
- Ask 0.5500 x --
- Day's Range
0.4000 - 0.4250 - 52 Week Range
0.3060 - 1.5700 - Volume
40 - Avg. Volume
0 - Market Cap (intraday)
8.067M - Beta (5Y Monthly) -0.51
- PE Ratio (TTM)
-- - EPS (TTM)
-0.4500 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Oncodesign Precision Medicine Société anonyme, a biopharmaceutical company, engages in the precision medicine business. The company's pipeline includes OPM-101, a potentially inhibitor of the RIPK2 target, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; OPM-102, a novel inhibitor that is in preclinical studies for the treatment of cancer; and OPM-201, a potential LRRK2 inhibitor, which is in Phase 1 clinical trial for the treatment of Parkinson's disease. It is also developing drugs for the treatment of pancreatic and other cancers. The company has a strategic collaboration agreement with Navigo Proteins GmbH for the discovery and development of new systemic radiotheranostic agents. Oncodesign Precision Medicine Société anonyme was founded in 1995 and is based in Dijon, France.
www.oncodesign.comRecent News: ZR8.F
View MorePerformance Overview: ZR8.F
Trailing total returns as of 4/15/2025, which may include dividends or other distributions. Benchmark is CAC 40 (^FCHI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ZR8.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ZR8.F
View MoreValuation Measures
Market Cap
9.08M
Enterprise Value
7.57M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
17.92
Price/Book (mrq)
2.07
Enterprise Value/Revenue
15.36
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
1.6M
Net Income Avi to Common (ttm)
-7.2M
Diluted EPS (ttm)
-0.4500
Balance Sheet and Cash Flow
Total Cash (mrq)
--
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--